Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design


Supplemental material placed on this supplemental material which has been supplied by the author(s) 



  Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) 




  Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) 


													J Immunother Cancer
	A						B		28z			BBz
										95%		97%
								GFP	CD3		
	C	CD4+ CAR+			CD4+ CAR+		CD8+ CAR+
		28z	BBz			28z		BBz		28z		BBz
	(-)MOLM14	76% 24%	88% 12%	73% 26% 82% 18%	92	8	97	3	93	7	93	7
	(+)MOLM14	20% 80% 50% 50%	31% 69% 52% 48%	42	58	80	20	58	42	78	22
		CD25				CD71						
				Qin H Qin H	, et al.	J Immunother Cancer	2022;	:e003149. 9	doi: 10.1136/jitc-2021-003149

J Immunother Cancer doi: 10.1136/jitc-2021-003149 :e003149. 9 2022; J Immunother Cancer , et al. Qin H BMJ BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer doi: 10.1136/jitc-2021-003149 :e003149. 9 2022; J Immunother Cancer , et al.
Haiying Qin, Lila Yang, John A Chukinas, Nirali N Shah, Samiksha Tarun, Marie Pouzolles, Christopher D Chien, Lisa M Niswander, Anthony R Welch, Naomi A Taylor, Sarah K Tasian, Terry J Fry
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design